Stock Events

Stock Events

Helus Pharma 

€9.36
498
+€0.00+0%Tuesday 18:17

Statistics

Day High
9.89
Day Low
9.88
52W High
9.89
52W Low
9.36
Volume
300
Avg. Volume
-
Mkt Cap
684.01M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 16Expected
Q2 2026
Next
-0.77
-0.72
-0.67
-0.62
Expected EPS
-0.62193225904752
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow R7E0.F. It's not an investment recommendation.
iShares Core Equity Portfolio
23
XEQT.TO
NVIDIA
20
NVDA
Vanguard S&P 500 Index
19
VFV.TO
Enbridge
17
ENB.TO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap1.65B
Compass Pathways operates in the psychedelic medicine space, focusing on psilocybin therapy for depression, directly competing with Cybin's psychedelic-based treatments.
AtaiBeckley
ATAI
Mkt Cap2.73B
ATAI Life Sciences is a biotech company with a focus on psychedelic and non-psychedelic compounds for mental health, making it a direct competitor to Cybin.
GH Research
GHRS
Mkt Cap1.57B
GH Research is involved in the development of therapeutics based on DMT for depression, competing in the same psychedelic treatment space as Cybin.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness focuses on psychedelic production and therapy, including psilocybin and MDMA, competing in the mental health treatment market alongside Cybin.
Revive Therapeutics
RVVTF
Mkt Cap9.15M
Revive Therapeutics is exploring the use of psychedelics for the treatment of various conditions, including mental health disorders, making it a competitor to Cybin.
PSYC
PSYC
Mkt Cap135,518
Psyched Wellness is focused on the development of psychedelic products, including Amanita Muscaria, competing in the broader psychedelic wellness market.
TripAdvisor
TRIP
Mkt Cap997.37M
Red Light Holland is involved in the production, growth, and sale of a premium brand of magic truffles, competing in the psychedelic substances market relevant to Cybin's interests.

About

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Show More
CEO
Michael I. Halstead
Employees
50
Country
Canada
ISIN
CA4234921076
WKN
000A42NG7

Listings

STU
DE
R7E.STU
MU
DE
R7E1.MU
STU
DE
R7E1.STU
F
DE
R7E0.F

0 Comments

Share your thoughts

FAQs

What is Helus Pharma stock price today?▼
The current price of R7E0.F is €9.36 EUR — it has increased by +0% in the past 24 hours. Watch Helus Pharma stock price performance more closely on the chart.
What is Helus Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Helus Pharma stocks are traded under the ticker R7E0.F.
What is Helus Pharma market cap?▼
Today Helus Pharma has the market capitalization of 684.01M
When is the next Helus Pharma earnings date?▼
Helus Pharma is going to release the next earnings report on November 16, 2026.
What were Helus Pharma earnings last quarter?▼
R7E0.F earnings for the last quarter are -0.77 EUR per share, whereas the estimation was -0.73 EUR resulting in a -5.57% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Helus Pharma have?▼
As of October 7, 2026, the company has 50 employees.
In which sector is Helus Pharma located?▼
Helus Pharma operates in the Health & Wellness sector.
When did Helus Pharma complete a stock split?▼
Helus Pharma has not had any recent stock splits.
Where is Helus Pharma headquartered?▼
Helus Pharma is headquartered in Toronto, Canada.